Abstract 190P
Background
APACT was a geographically diverse trial with study sites worldwide, including in Asia; here, we report outcomes from Asian sites.
Methods
Treatment-naive pts with histologically confirmed PC, R0/R1 resection, CA 19-9 < 100 U/mL, and ECOG PS ≤ 1 received 6 cycles of nab-P 125 mg/m2 + G 1000 mg/m2 or G 1000 mg/m2 on days 1, 8, and 15. Stratification factors were resection (R0/R1) and lymph node (LN+/−) status. The primary endpoint was disease-free survival (DFS) by independent review. Secondary endpoints were overall survival (OS) and safety.
Results
At Asian sites (Hong Kong, Korea, Singapore, and Taiwan), 108 pts (of 866 pts from the ITT population) were randomized to nab-P/G (n = 55) or G (n = 53). Median age was 61 years. Most pts had ECOG PS 0 (64%), LN+ disease (61%), and R0 resection (86%). Six treatment cycles were administered in 76% (nab-P/G) vs 77% (G) of pts. Data cutoff was April 3, 2020; median follow-up for OS was 52.6 months. Median independently assessed DFS was 27.6 (nab-P/G) vs 22.6 (G) months (Table); investigator-assessed DFS was 18.0 vs 11.9 months. Median OS was 46.8 (nab-P/G) vs 40.6 (G) months. Analgesics (nab-P/G) and treatments for indigestion (G) were the most common concomitant medications. The most common grade ≥ 3 hematologic and nonhematologic treatment-emergent adverse events (AEs) with nab-P/G vs G were neutropenia (36.4% vs 26.9%) and peripheral neuropathy (10.9% vs 0%). All dose reductions (36 [nab-P/G] vs 21 [G]) were due to AEs (most common, neutropenia); 4 (nab-P/G) vs 0 (G) pts discontinued treatment due to AEs Table: 190P
Outcome | nab-P/G | G | HR (95% CI) | P Value | ||
n/N | Median (95% CI), months | n/N | Median (95% CI), months | |||
Asian populationa | ||||||
Ind. DFS | 21/55 | 27.6 (16.36-NA) | 24/53 | 22.6 (10.84-NA) | 0.73 (0.405-1.331) | – |
Inv. DFS | 34/55 | 18.0 (11.96-27.63) | 35/53 | 11.9 (8.28-21.88) | 0.73 (0.453-1.178) | – |
OSb | 30/ 55 | 46.8 (27.01-NA) | 32/53 | 40.6 (24.21-48.03) | 0.85 (0.513-1.398) | – |
ITT population | ||||||
Ind. DFS | 226/ 432 | 19.4 (16.62-21.91) | 213/ 434 | 18.8 (13.83-20.30) | 0.88 (0.729-1.063) | .1824 |
Inv. DFS | 282/ 432 | 16.6 (14.55-19.29) | 289/434 | 13.7 (11.24-16.00) | 0.82 (0.694-0.965) | .0168 |
OSb | 248/432 | 41.8 (35.55-47.28) | 263/434 | 37.7 (31.11-40.51) | 0.82 (0.687-0.973) | .0232 |
a Pts were from sites in Hong Kong (n = 4), Republic of Korea (n = 51), Singapore (n = 6), and Taiwan (n = 47). b Based on an April 3, 2020 data cutoff.CI, confidence interval; G, gemcitabine; HR, hazard ratio; Ind. DFS, disease-free survival by independent radiological review; Inv. DFS, disease-free survival by investigator review; ITT, intention-to-treat; NA, not achieved; nab-P, nab-paclitaxel; OS, overall survival.
.Conclusions
Consistent with outcomes in the ITT population, DFS and OS were numerically longer with nab-P/G vs G in the Asian cohort. The nab-P/G safety profile was consistent with that seen in the overall treated population.
Clinical trial identification
2013-003398-91; NCT01964430.
Editorial acknowledgement
Writing assistance was provided by Mohan Harihar, of MediTech Media, Ltd., and funded by Bristol-Myers Squibb Company. The authors are fully responsible for all content and editorial decisions for this manuscript.
Legal entity responsible for the study
Bristol-Myers Squibb Company.
Funding
Bristol-Myers Squibb Company.
Disclosure
J. Bendell: Research grant/Funding (institution): Gilead, Genentech-Roche, Bristol-Myers Squibb, Five Prime, Eli Lilly & Co., Merck, MedImmune, Celgene, EMD Serono, Taiho, Macrogenics, GlaxoSmithKline, Novartis, OncoMed, LEAP, TG Therapeutics, AstraZeneca, BI, Daiichi Sankyo, Bayer, Incyte, Apexigen, Kol; Advisory/Consultancy: Gilead, Genentech-Roche, Bristol-Myers Squibb, Five Prime, Eli Lilly & Co., Merck, MedImmune, Celgene, Taiho, Macrogenics, GlaxoSmithKline, Novartis, OncoMed, LEAP, TG Therapeutics, AstraZeneca, BI, Daiichi Sankyo, Bayer, Incyte, Apexigen, Array, Sanofi,. B. Garlipp: Research grant/Funding (self): Sirtex; Honoraria (self): Sirtex, Roche, Amgen, Pfizer, Celgene, Merck and Novartis; Advisory/Consultancy: Sirtex, Roche and Amgen; Travel/Accommodation/Expenses: Merck, Amgen, Celgene, B. Braun Travacare. M. Karthaus: Advisory/Consultancy, Travel/Accommodation/Expenses: Helsinn and Riemser. B. Lu: Shareholder/Stockholder/Stock options, Full/Part-time employment: Bristol-Myers Squibb. D. McGovern: Shareholder/Stockholder/Stock options, Full/Part-time employment: Bristol-Myers Squibb. S. Banerjee: Shareholder/Stockholder/Stock options, Full/Part-time employment: Bristol-Myers Squibb. M. Tempero: Research grant/Funding (self): AbbVie, AstraZeneca, Advance Medical, BioPharm Communications, Bristol-Myers Squibb, CPRIT, Eisai, Halozyme, Ignyta, Immunovia, Pharmacyclics LLC, PharmaCyte Biotech, Tocagen. D-Y. Oh: Research grant/Funding (self): AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
104P - Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III study
Presenter: Shukui Qin
Session: e-Poster Display Session
105P - Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study
Presenter: Tsai-Sheng Yang
Session: e-Poster Display Session
106P - Efficacy and tolerability of capecitabine and mitomycin-C based concurrent radiotherapy in patients with anal canal cancer
Presenter: Prabhat Bhargava
Session: e-Poster Display Session
107P - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study
Presenter: Timothy Price
Session: e-Poster Display Session
108P - Comparative analysis of two-stage hepatectomy and enhanced one-stage hepatectomy in the setting of bilobar colorectal liver metastases
Presenter: Hayk Torgomyan
Session: e-Poster Display Session
109P - Efficacy and safety of biweekly or triweekly XELOX regimen for adjuvant chemotherapy of colorectal cancer
Presenter: hangyu zhang
Session: e-Poster Display Session
110P - Analysis for stereotactic body radiotherapy (SBRT) effect for colorectal liver metastases
Presenter: Wei Zou
Session: e-Poster Display Session
111P - A meta-analysis study on safety and effectiveness comparison between FOLFOX and XELOX regiments on advanced stage colorectal cancer
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
112P - Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study
Presenter: Takayuki Yoshino
Session: e-Poster Display Session
122P - Nomogram to predict short-term effect of radiotherapy based on pre/post-treatment inflammatory biomarkers and their dynamic changes in esophageal squamous cell carcinoma
Presenter: Shuai Liang
Session: e-Poster Display Session